Hormone receptor-positive/HER2-negative (HR+/HER2−) breast cancers (BC) account for almost two-thirds of BC diagnoses1 and are well known to be a clinically heterogenous subgroup of BCs. This evidence concerns the gene NR4A1 and breast cancer.